Cargando…
Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1
BACKGROUND: Inefficient T-cell access to the tumor microenvironment (TME) is among the causes of tumor immune-resistance. Previous evidence demonstrated that targeting CXCR4 improves anti-PD-1/PD-L1 efficacy reshaping TME. To evaluate the role of newly developed CXCR4 antagonists (PCT/IB2011/000120/...
Autores principales: | D’Alterio, Crescenzo, Buoncervello, Maria, Ieranò, Caterina, Napolitano, Maria, Portella, Luigi, Rea, Giuseppina, Barbieri, Antonio, Luciano, Antonio, Scognamiglio, Giosuè, Tatangelo, Fabiana, Anniciello, Anna Maria, Monaco, Mario, Cavalcanti, Ernesta, Maiolino, Piera, Romagnoli, Giulia, Arra, Claudio, Botti, Gerardo, Gabriele, Lucia, Scala, Stefania |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6819555/ https://www.ncbi.nlm.nih.gov/pubmed/31661001 http://dx.doi.org/10.1186/s13046-019-1420-8 |
Ejemplares similares
-
Variability in Immunohistochemical Detection of Programmed Death Ligand 1 (PD-L1) in Cancer Tissue Types
por: Scognamiglio, Giosuè, et al.
Publicado: (2016) -
New CXCR4 Antagonist Peptide R (Pep R) Improves Standard Therapy in Colorectal Cancer
por: D’Alterio, Crescenzo, et al.
Publicado: (2020) -
CXCR4-CXCL12-CXCR7 and PD-1/PD-L1 in Pancreatic Cancer: CXCL12 Predicts Survival of Radically Resected Patients
por: D’Alterio, Crescenzo, et al.
Publicado: (2022) -
Inhibition of stromal CXCR4 impairs development of lung metastases
por: D’Alterio, Crescenzo, et al.
Publicado: (2012) -
In PD-1+ human colon cancer cells NIVOLUMAB promotes survival and could protect tumor cells from conventional therapies
por: Ieranò, Caterina, et al.
Publicado: (2022)